Given the decreased risk of major adverse cardiovascular events as seen with the use of GLP-1RA and SGLT-2 inhibitors, additional studies are urgently needed for newer classes of diabetes medications to assess the incidence of AF through potential interactions between oxidative stress, atrial fibrosis, and autonomic remodeling. The gene discussed is SLC5A2; the disease is diabetes mellitus.